ImmuPharma Financial Statements From 2010 to 2026
ImmuPharma Plc's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing ImmuPharma Plc's valuation are provided below:ImmuPharma Plc does not presently have any fundamental trends for analysis.
This module can also supplement various ImmuPharma Plc Technical models . Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in inflation.
Check ImmuPharma Plc financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ImmuPharma Plc's main balance sheet or income statement drivers, such as , as well as many indicators such as . ImmuPharma financial statements analysis is a perfect complement when working with ImmuPharma Plc Valuation or Volatility modules.
ImmuPharma |
ImmuPharma Plc Company Operating Margin Analysis
ImmuPharma Plc's Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Current ImmuPharma Plc Operating Margin | (48.47) % |
Most of ImmuPharma Plc's fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, ImmuPharma Plc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
CompetitionBased on the recorded statements, ImmuPharma Plc has an Operating Margin of -48.4681%. This is 38.16% higher than that of the Healthcare sector and 56.75% lower than that of the Biotechnology industry. The operating margin for all United States stocks is notably higher than that of the company.
ImmuPharma Plc Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining ImmuPharma Plc's current stock value. Our valuation model uses many indicators to compare ImmuPharma Plc value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across ImmuPharma Plc competition to find correlations between indicators driving ImmuPharma Plc's intrinsic value. More Info.ImmuPharma Plc is rated fourth overall in return on equity category among its peers. It is currently regarded as number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the ImmuPharma Plc's earnings, one of the primary drivers of an investment's value.Currently Active Assets on Macroaxis
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in inflation. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Other Consideration for investing in ImmuPharma Pink Sheet
If you are still planning to invest in ImmuPharma Plc check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the ImmuPharma Plc's history and understand the potential risks before investing.
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |